Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 7,200 shares, a decrease of 82.4% from the January 31st total of 41,000 shares. Based on an average daily volume of 141,500 shares, the short-interest ratio is currently 0.1 days.

Bioxytran Trading Down 4.8 %

OTCMKTS:BIXT traded down $0.00 during midday trading on Thursday, hitting $0.08. 20,000 shares of the company were exchanged, compared to its average volume of 155,838. Bioxytran has a fifty-two week low of $0.06 and a fifty-two week high of $0.15. The company has a market capitalization of $6.87 million, a PE ratio of -7.80 and a beta of -0.68. The company has a fifty day simple moving average of $0.09 and a 200 day simple moving average of $0.09.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.